During the corresponding time, Atricure Inc recorded a revenue increase by 13.38 % year on year, sequentially revenue grew by 9.47 %. While revenue at the Atricure Inc 's corporate clients
Atricure Inc's Comment on Sales, Marketing and Customers
The company manufactures and sells single-use disposable radiofrequency (RF) products, including the Isolator Synergy Clamps, EnCompass clamp, EnCapture clamp, multifunctional pens, and linear ablation devices. These products are primarily used for cardiac tissue ablation and the treatment of cardiac arrhythmias. They are distributed to surgical distributors and utilized by cardiac surgeons, often in conjunction with other devices.
The Isolator Synergy Ablation System is FDA approved for treating persistent and long-standing persistent atrial fibrillation (Afib) during open-heart surgeries and complies with EU Medical Device Regulations for distribution in the European Union and other countries. The EnCompass clamp was launched in the United States in 2022, and the EnCapture clamp received clearance in 2024; both are designed to enhance surgical ablation efficiency and engagement with cardiac tissue. Clinical trials, including ABLATE, DEEP AF IDE, HEAL-IST, and BoxX-NoAF, are ongoing to evaluate the effectiveness of these products.
The multifunctional pens and linear ablation devices have received FDA clearance and comply with EU Medical Device Regulations, allowing their sale in the US, EU, and other markets. The company serves market segments including cardiac surgeons performing open and minimally invasive ablation procedures, distributors, and patients undergoing cardiac surgery requiring arrhythmia treatment.
Innovative Strides and Financial Ambitions: AtriCure’s Path to Preeminence in Cardiovascular Therapies In a series of groundbreaking announcements, AtriCure, Inc. (Nasdaq: ATRC) is demonstrating a robust commitment to advancing cardiovascular health through innovative clinical trials, cutting-edge device implementation, and strategic financial aspirations. As the company marches towards a promising future, the impact of these developments on AtriCure’s market position cannot be overstated. Clinical Triumph: The BoxX-NoAF Clinical Trial AtriCure has made significant strides with the initiation of the Box Lesion Creation with Left Atrial Appendage Exclusion to Reduce the Occurrence of New-onset Atrial Fi...
In the ever-evolving landscape of medical technology, few companies are making as significant an impact as AtriCure, Inc. (Nasdaq: ATRC). Based in Mason, Ohio, this leading innovator specializes in surgical treatments and therapies aimed at addressing atrial fibrillation (Afib), a common and potentially dangerous heart rhythm disorder. With their recent developments and growing international presence, AtriCure is uniquely positioned to influence the future of cardiovascular care. Engaging in Key Discussions at the Piper Sandler Conference On December 4, 2024, AtriCure s management will participate in a fireside discussion at the prestigious Piper Sandler 36th Annual Healthcare Conference. Scheduled for 9:00 ...
In an exciting development for the medical technology industry, AtriCure, Inc. (Nasdaq: ATRC), headquartered in Mason, Ohio, has received CE-Mark approval to market its EnCompass Clamp across countries in the European Union. This marks a significant milestone in AtriCure s ongoing efforts to expand its global footprint and provide innovative surgical solutions for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management.The EnCompass Clamp, which previously received FDA 510(k) clearance in the United States, is designed to simplify complex surgical procedures aimed at treating Afib, a common and potentially serious heart rhythm disorder. Afib affects millions of ...
AtriCure, Inc. a prominent player in medical innovation, has received an expanded indication for its AtriClip devices from the CE Mark authority in Europe. This advancement allows the use of AtriClip in treating patients with atrial fibrillation (Afib) who are at high risk of stroke. Overview of AtriCure and AtriClip Technology Headquartered in Mason, Ohio, AtriCure specializes in surgical solutions and therapies related to Afib, left atrial appendage (LAA) management, and postoperative pain management. The company’s flagship product, the AtriClip, is specifically designed to occlude the left atrial appendage a common site for blood clot formation in Afib patients, which significantly increases the risk o...
AtriCure Revolutionizes Atrial Fibrillation Treatment with the Launch of AtriClip and cryoSPHERE+ ProbeMASON, Ohio - AtriCure, Inc. (Nasdaq: ATRC), a pioneering medical technology company specializing in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, has announced the launch of two innovative products - AtriClip and cryoSPHERE+ cryoablation probe. These developments mark significant advancements in the field of cardiovascular surgery, offering improved treatment options and patient outcomes.The AtriClip device, designed for Afib and LAA management, provides surgeons with a unique solution to reduce the risk of stro...
Atricure Inc’s Comment on Sales, Marketing and Customers
The company manufactures and sells single-use disposable radiofrequency (RF) products, including the Isolator Synergy Clamps, EnCompass clamp, EnCapture clamp, multifunctional pens, and linear ablation devices. These products are primarily used for cardiac tissue ablation and the treatment of cardiac arrhythmias. They are distributed to surgical distributors and utilized by cardiac surgeons, often in conjunction with other devices.
The Isolator Synergy Ablation System is FDA approved for treating persistent and long-standing persistent atrial fibrillation (Afib) during open-heart surgeries and complies with EU Medical Device Regulations for distribution in the European Union and other countries. The EnCompass clamp was launched in the United States in 2022, and the EnCapture clamp received clearance in 2024; both are designed to enhance surgical ablation efficiency and engagement with cardiac tissue. Clinical trials, including ABLATE, DEEP AF IDE, HEAL-IST, and BoxX-NoAF, are ongoing to evaluate the effectiveness of these products.
The multifunctional pens and linear ablation devices have received FDA clearance and comply with EU Medical Device Regulations, allowing their sale in the US, EU, and other markets. The company serves market segments including cardiac surgeons performing open and minimally invasive ablation procedures, distributors, and patients undergoing cardiac surgery requiring arrhythmia treatment.
Sources:
Atricure Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Atricure Inc’s corporate clients.
For your research, we’ve provided 9 tables on Atricure Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
13.51 %